Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Current Assets (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Current Assets for 15 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 27.16% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 27.16% increase, with the full-year FY2024 number at $1.9 million, down 72.95% from a year prior.
  • Current Assets was $2.9 million for Q3 2025 at NovaBay Pharmaceuticals, down from $6.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $13.2 million in Q4 2021 to a low of $1.9 million in Q4 2024.
  • A 5-year average of $8.4 million and a median of $9.5 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 79.91% in 2024, then soared 171.42% in 2025.
  • NovaBay Pharmaceuticals' Current Assets stood at $13.2 million in 2021, then fell by 13.96% to $11.3 million in 2022, then crashed by 36.87% to $7.2 million in 2023, then plummeted by 72.95% to $1.9 million in 2024, then skyrocketed by 49.77% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Current Assets are $2.9 million (Q3 2025), $6.1 million (Q2 2025), and $9.0 million (Q1 2025).